News

Breckenridge expects to file an abbreviated new drug application (ANDA) with the FDA in January 2008. Upon approval by the FDA, Helm will supply and Breckenridge will market

APD668 is an oral drug candidate discovered by Arena and being investigated under a partnership with Ortho-McNeil Pharmaceutical. Ortho-McNeil’s initial clinical studies evaluated healthy volunteers and patients with

The study is designed to demonstrate that the single-injection Monovisc safely provides symptomatic relief of knee pain and associated dysfunction in patients with osteoarthritis. Anika plans to enroll

The Phase IIa human clinical trial to be conducted in the US is designed to investigate the safety and clinical outcomes of topically applied GLYC-101 compared to placebo

The initial phase of the multiple ascending dose (MAD) study utilized three times per day dosing (tid) for 14 days in healthy obese subjects exposed to a high

Under the terms of the collaboration agreement, Seattle Genetics received an upfront payment of $60 million in February 2007, and is entitled to receive potential milestone payments exceeding

Greatbatch’s acquisition of Precimed was structured as a stock purchase. In exchange for the outstanding shares of Precimed, Greatbatch paid approximately CHF123 million in cash and, under terms

The uniquely designed Phase I dose-escalation study in adult patients with advanced cancer will investigate the safety and preliminary efficacy of CNDO101 (5-imino-13 deoxy-doxorubicin). The trial has eight

In the initial Phase I part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the Phase II part